RESUMO
El sarcoma de la arteria pulmonar es una patología rara y de pronóstico letal. Se desconoce su etiología, pero con mayor frecuencia afecta al tronco de la arteria pulmonar y a sus ramas principales. Los estudios complementarios mediante resonancia magnética con gadolinio y tomografía por emisión de positrones son de utilidad para orientar el diagnóstico, pero este sólo se puede establecer al realizar un estudio histológico. Presentamos este caso dada la baja incidencia y su importancia para el diagnóstico diferencial del tromboembolismo pulmonar.
Pulmonary artery sarcoma is a rare tumor with lethal prognosis. Its etiology is unknown; most frequently the pulmonary trunk and its main branches are affected. Magnetic resonance imaging with gadolinium and positron emission tomography are complementary studies that can guide the diagnosis, but this can only be established with the histological study. We present this case because of the low incidence and its importance in the differential diagnosis of pulmonary thromboembolism.
Assuntos
Artéria Pulmonar , SarcomaRESUMO
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
Assuntos
Anticorpos Monoclonais Murinos/efeitos adversos , Antineoplásicos/efeitos adversos , Doenças Pulmonares Intersticiais/induzido quimicamente , Idoso , Feminino , Humanos , Doenças Pulmonares Intersticiais/diagnóstico por imagem , Linfoma Folicular/tratamento farmacológico , Rituximab , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
La introducción en la práctica clínica del anticuerpo anti-CD20 rituximab ha mejorado sustancialmente el pronóstico de diversas enfermedades autoinmunes y hematológicas. Con el incremento de su uso ha aumentado el registro de efectos adversos, entre ellos la toxicidad pulmonar. Una de sus complicaciones más serias es la enfermedad pulmonar intersticial, entidad potencialmente fatal que debe ser considerada en pacientes que han recibido rituximab y presentan disnea, fiebre y tos sin clara evidencia de infección. Presentamos un caso de enfermedad pulmonar intersticial asociada a rituximab.(AU)
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.(AU)
Assuntos
Idoso , Feminino , Humanos , Anticorpos Monoclonais Murinos/efeitos adversos , Antineoplásicos/efeitos adversos , Doenças Pulmonares Intersticiais/induzido quimicamente , Doenças Pulmonares Intersticiais/diagnóstico por imagem , Linfoma Folicular/tratamento farmacológico , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
La introducción en la práctica clínica del anticuerpo anti-CD20 rituximab ha mejorado sustancialmente el pronóstico de diversas enfermedades autoinmunes y hematológicas. Con el incremento de su uso ha aumentado el registro de efectos adversos, entre ellos la toxicidad pulmonar. Una de sus complicaciones más serias es la enfermedad pulmonar intersticial, entidad potencialmente fatal que debe ser considerada en pacientes que han recibido rituximab y presentan disnea, fiebre y tos sin clara evidencia de infección. Presentamos un caso de enfermedad pulmonar intersticial asociada a rituximab.
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
Assuntos
Idoso , Feminino , Humanos , Anticorpos Monoclonais Murinos/efeitos adversos , Antineoplásicos/efeitos adversos , Doenças Pulmonares Intersticiais/induzido quimicamente , Doenças Pulmonares Intersticiais , Linfoma Folicular/tratamento farmacológico , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
